R
Robert S. de Jong
Publications - 4
Citations - 672
Robert S. de Jong is an academic researcher. The author has contributed to research in topics: Capecitabine & Oxaliplatin. The author has an hindex of 4, co-authored 4 publications receiving 617 citations.
Papers
More filters
Journal ArticleDOI
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Miriam Koopman,Ninja Antonini,Joep Douma,Jaap Wals,Aafke H. Honkoop,Frans L. G. Erdkamp,Robert S. de Jong,C.J. Rodenburg,Gerard Vreugdenhil,Olaf J. L. Loosveld,Aart van Bochove,Harm Sinnige,Geert-Jan Creemers,Margot E T Tesselaar,Peter H. Th J. Slee,Marjon J. B. P. Werter,Linda Mol,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: Combination treatment does not significantly improve overall survival compared with the sequential use of cytotoxic drugs in advanced colorectal cancer, and sequential treatment remains a valid option for patients with advanced coloresceptic cancer.
Journal ArticleDOI
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Didier Meulendijks,Laurens V. Beerepoot,Henk Boot,Jan Willem B. de Groot,Maartje Los,James E. Boers,Steven A L W Vanhoutvin,Marco B. Polee,Aart Beeker,Johanna E.A. Portielje,Robert S. de Jong,S. H. Goey,Maria Kuiper,Karolina Sikorska,Jos H. Beijnen,Jos H. Beijnen,Margot E T Tesselaar,Jan H.M. Schellens,Jan H.M. Schellens,Annemieke Cats +19 more
TL;DR: B-DOCT is a safe and active combination in Her2-positive GC, supporting further investigations of DOC with HER2/vascular endothelial growth factor (VEGF) inhibition in HER2- positive GC.
Journal ArticleDOI
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study
Didier Meulendijks,Jan Willem B. de Groot,Maartje Los,James E. Boers,Laurens V. Beerepoot,Marco B. Polee,Aart Beeker,Johanna E.A. Portielje,S. H. Goey,Robert S. de Jong,Steven A L W Vanhoutvin,Maria Kuiper,Karolina Sikorska,Dick Pluim,Jos H. Beijnen,Jan H.M. Schellens,Cecile Grootscholten,M. E. T. Tesselaar,Annemieke Cats +18 more
TL;DR: The current study was a multicenter, single‐arm, phase 2 study performed to investigate the feasibility and efficacy of bevacizumab combined with docetaxel, oxaliplatin, and capecitabine in patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative, previously untreated, gastric or gastroesophageal adenocarcinoma.
Journal ArticleDOI
Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy
Maurice C. van Staveren,André B.P. van Kuilenburg,Henk-Jan Guchelaar,Judith Meijer,Cornelis J. A. Punt,Robert S. de Jong,Hans Gelderblom,J. G. Maring +7 more
TL;DR: The high sensitivity of the U/DHU ratio at t = 120 min for detecting DPD deficiency, as defined by D PD activity in PBMCs, showed that the oral U loading dose can effectively identify patients with reduced DPD activity.